


S. Korea drops vaunted 'test and trace' strategy as Omicron surges

February 9 2022



Credit: CC0 Public Domain

South Korea said Wednesday it was dropping its vaunted "trace, test and treat" programme as a surge in Omicron cases threatens to overwhelm the country's healthcare system.

At the start of the pandemic in 2020, South Korea was hit by one of the worst early outbreaks of the disease outside China but brought it under



control with mass testing and aggressive contact tracing.

The strategy earned the country widespread praise, but Seoul has now decided to drop the system after surpassing one million infections over the weekend due to the rapid spread of Omicron.

The "trace, test and treat" approach is "difficult to operate due to <u>limited</u> resources" and has "excessively high social and economic costs", said Sohn Young-rae, a senior health official.

South Korea's daily caseload hit a record high of 49,567 on Tuesday, with <u>health authorities</u> saying the number could hit 170,000 later this month.

The figure has more than doubled in less than a week.

A new set of measures to manage the virus is taking effect in stages starting this month, and will refocus resources on the most vulnerable, health officials said.

The aim is to diagnose and treat high-risk groups to "prevent the collapse of the medical system and the deterioration of social and economic functions", Sohn added.

Authorities will be prioritising tests for people aged 60 or older.

Previously, anyone testing positive was sent to a government centre for treatment and quarantine, but now asymptomatic patients are being told to stay at home.

Around 85 percent of the country's 52 million population have been double vaccinated, according to the Korea Disease Control and Prevention Agency.



© 2022 AFP

Citation: S. Korea drops vaunted 'test and trace' strategy as Omicron surges (2022, February 9) retrieved 9 May 2024 from

https://medicalxpress.com/news/2022-02-korea-vaunted-strategy-omicron-surges.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.